

# INDEX

## A

ablation (tumor)  
radiofrequency, 139, 141, 157, 159  
thermal, 139, 141, 157, 159  
acetaminophen, 2, 9, 86, 87, 88, 90, 91, 93  
acinus, 31, 35, 36  
acute liver failure, 11, 13, 16, 17, 48-51, 62, 87, 92, 101, 104, 106, 114, 119, 130, 133, 134  
Acute Liver Failure Study Group (ALFSG), 51, 92, 134  
Agency for Healthcare Research and Quality (AHRQ), 24  
Alagille syndrome, 2, 9, 15, 16, 53, 57, 101, 102, 105, 109  
AIDS Clinical Trial Group (ACTG), 76  
albumin, 45, 120, 131  
alcohol/alcoholic liver disease—See fatty liver disease  
alpha-1 anti-trypsin deficiency, 2, 9, 15, 17, 50, 101, 105, 109, 137, 138  
alpha-fetoprotein, 45  
aminotransferases (serum), 14, 39, 74, 83, 88, 92, 93  
animal models, 6, 21, 33, 35, 40, 41, 43, 46, 47, 50, 51, 57, 58, 63-65, 68, 69, 72, 76, 81-85, 89, 92, 93, 96-99, 103, 105, 106, 115, 116, 122, 133, 138, 139, 143, 146-148, 150, 156, 159  
antibody and phage display, 140  
anti-cytokine therapy, 80, 82, 83, 85, 122, 126  
antioxidants, 75, 80, 81, 91, 93, 142  
antiviral therapy  
for hepatitis virus infection, 20, 61-69, 72, 75, 104, 123, 124, 166  
resistance to (nonresponders), 2, 66-69  
antiretroviral therapy (ART) for HIV infection, 19, 71, 72, 74  
apoptosis, 40, 45, 89, 112  
anti-apoptotic therapy, 42  
artificial/bioartificial liver device, 31, 133, 134  
ascites, 6, 11, 20, 129-134  
autoimmune hepatitis—See hepatitis, autoimmune  
autoimmune liver disease—See hepatitis, autoimmune; primary biliary cirrhosis, primary sclerosing cholangitis

## B

bacterial peritonitis, 6, 129, 131  
bariatric surgery, 84, 85  
Longitudinal Assessment of Bariatric Surgery (LABS), 85  
benign recurrent intrahepatic cholestasis (BRIC), 55  
bile, 52-29, 87, 94-97, 99-102, 104, 110, 115, 144-150, 156  
bile canaliculus, 30, 33, 54-56  
bile ducts/biliary tract, 1, 6, 10, 11, 15, 19, 31, 45, 46, 52, 53, 57, 87, 94-97, 99-101, 146-150, 153  
bile salt/acid, 5, 30-34, 52-59, 146  
bile salt export pump (BSEP), 53  
biliary atresia, 2, 6, 15-17, 53, 100-106, 119, 145, 167  
Biliary Atresia Research Consortium (BARC), 59, 105  
Kasai procedure (hepatopportoenterostomy), 100-104  
biliary ductules—See canals of Hering  
biliary pain, 147, 150  
bilirubin, 5, 52-29, 120, 145, 147  
biomarkers, 42, 43, 49-51, 74, 76, 82, 83, 91, 93, 98, 99, 103-106, 122, 123, 126, 140-143, 147-150, 167  
Byler disease—See progressive familial intrahepatic cholestasis

## C

canals of Hering, 46  
cancer—See hepatocellular carcinoma, cholangiocarcinoma, and hepatoblastoma  
carcinogenesis, 5, 6, 45, 46, 48, 51, 104, 136, 138, 139, 141-143  
cell/organ culture, 6, 12, 35, 36, 46, 48, 59, 62, 63, 65, 68, 69, 73, 76  
cell cycle, 33, 47, 48  
cell junctions (gap, tight), 33-36  
cell signaling, 33-36, 40, 41, 43-49, 56, 57, 83, 89-91, 102, 111, 112, 122, 140  
Center for Scientific Review (CSR), 84, 171, 172

Centers for Disease Control and Prevention (CDC), 12, 13, 17-19, 24, 60, 70, 84, 105, 116, 177  
cerebrotendinous xanthomatosis (CTX), 55  
chemoembolization (transarterial), 124, 139, 141, 142  
chemotherapy, 121, 124, 126, 140, 141  
cholangiocarcinoma, 1, 15, 96, 98, 99, 137, 145, 148-150, 153, 165  
cholangiocyte, 32, 34-36, 40, 46, 48, 57, 112, 115  
cholecystectomy, 14, 20, 146-148, 167  
cholecystitis, 145, 147, 148  
cholestasis, 2, 15, 52, 53, 59, 95, 96, 100, 101, 103  
cholesterol, 31, 33, 34, 50, 52-59, 81, 121, 144-150  
chronic liver disease, 1, 2, 5, 6, 9-16, 19, 20, 39, 42, 43, 45, 46, 50, 55, 58, 61-66, 79, 82, 87, 91-93, 101, 102, 105, 110, 112, 113, 116, 119-121, 128-134, 136-140, 148, 155, 156, 166-168  
cilia (biliary), 32, 55  
cirrhosis, 1, 2, 5, 6, 9, 11, 14-20, 32, 38-42, 45, 46, 48, 53, 55, 58, 61, 63, 75, 79-81, 83, 84, 87, 92, 94-96, 101, 109, 110, 112, 114, 119, 121, 129, 142, 155, 156, 165-167  
    cryptogenic, 15-17, 79, 83, 119, 137, 140  
clinical trials, 3, 28, 42, 64, 67, 75, 76, 83-85, 88, 91, 92, 103-106, 116, 123-125, 134, 142, 149, 157  
collagen, 32, 38-40, 42  
computed tomography (CT), 139, 152-154, 156, 159  
congenital hepatic fibrosis, 6, 108-110, 112, 115, 116  
copper overload—See Wilson disease  
covalently closed circular DNA (cccDNA), 65, 67, 69  
creatinine, 120  
Crigler-Najjar syndrome, 50, 54, 56, 58, 119, 124  
cryptosporidiosis, 71  
cyclin dependent kinases, 47  
cytochrome (CYP), 83, 86, 88  
cystic fibrosis, 6, 55, 101, 108-110, 112, 115, 116, 145  
cytokines, 33, 34, 41, 44-47, 49, 66, 73, 79, 80, 82, 83, 85, 89, 91, 97, 112, 122, 126  
    anti-inflammatory, 97  
    pro-inflammatory, 82, 91, 97  
cytomegalovirus, 71  
cytoskeleton, 33, 34

## D

development, 35, 44-51, 59, 103, 106  
diabetes, 14, 18, 19, 55, 73, 79, 80, 82, 84, 85, 97, 99, 104, 121, 138  
diagnostic criteria, 98, 99, 104-106, 140, 155, 158, 159, 168  
differentiation, 32, 33, 45-49, 102, 105  
Department of Veterans Affairs (VA), 24, 84, 85, 116  
Digestive Diseases Interagency Coordinating Committee (DDICC), 3, 4, 25, 26, 161, 162  
    Liver Disease Subcommittee (LDS), 3, 4, 6, 25, 26, 161, 162  
disease  
    burden, 1-3, 9-19, 26, 28, 62, 72, 91, 93, 102, 103, 106, 110, 138, 167  
    grading, 6, 74, 85, 103, 104, 106, 132, 133, 140, 143, 168  
    staging, 68, 74, 85, 103-106, 122, 140, 143, 148-150, 153, 168  
Dubin-Johnson syndrome, 54, 56  
drug-induced liver disease, 1, 2, 11, 14, 17, 19, 42, 53, 59, 71, 76, 76, 77, 82, 86-93, 101  
    Drug-Induced Liver Injury Network (DILIN), 59, 92  
    idiosyncratic, 87-90, 92, 93  
        allergic, 87-90, 93  
        non-allergic, 87, 89, 90, 93  
        signature, 87, 90, 91, 93

## E

embryogenesis, 45, 46, 105  
end-stage liver disease, 14, 16, 21, 72, 79, 95, 101, 102, 119-121, 165, 166  
endoderm, 44, 45, 47, 48, 51  
endoplasmic reticulum, 32, 56  
endoscopic retrograde cholangiopancreatography (ERCP), 94, 95, 146, 147, 153  
endothelial cell, 31, 32, 35, 36, 40, 41, 44-46, 48, 49, 73, 89, 154  
enterohepatic circulation (EHC), 52, 53, 145, 147, 150  
environmental hepatotoxins, 1, 5, 11, 40, 66, 74, 87, 89, 90, 96, 98, 99, 148  
Epstein Barr Virus, 123  
esophageal varices, 11, 19, 129, 131-133  
extracellular matrix, 32, 35, 40

**F**

fatigue, 2, 11, 20, 39, 129  
fatty acid, 79-83  
fatty liver disease  
alcoholic, 1, 5, 6, 11, 14, 16, 17, 19, 71, 78-85, 112 113, 116, 119, 137, 140, 166  
nonalcoholic, 1, 2, 5, 6, 11, 14, 42, 71, 73-75, 78-92, 101, 104, 112, 119, 137, 138, 140, 166  
nonalcoholic steatohepatitis, 2, 11, 14, 42, 71, 75, 78-85, 92, 101, 104, 110, 112, 115, 119, 138  
Nonalcoholic Steatohepatitis Clinical Research Network (NASHCRN), 84  
steatosis, 75, 80-83, 85  
fibrogenesis, 32, 42, 137  
fibrosis, 5, 6, 14, 38-43, 48, 49, 51, 53, 74, 76, 77, 79-81, 83, 96, 97, 101, 104, 109, 110, 112, 115, 116, 130, 153, 156, 157, 159, 166, 167  
anti-fibrotic therapy, 85, 104  
Fogarty International Center (FIC), 22, 23, 171  
Food and Drug Administration (FDA), 14, 24, 88, 92, 93, 116, 172, 174

**G**

gallbladder disease, 1, 2, 6, 9, 11, 14, 19-21, 24, 54, 55, 144-150, 153, 165, 167  
gallstones/cholelithiasis, 1, 2, 6, 11, 14, 19-21, 24, 54, 55, 144-150, 153, 165, 167  
cholesterol gallstones, 55, 144-150  
gallstone pancreatitis, 145  
Helicobacter, 147, 150  
microlithiasis, 147, 150  
nucleation factors, 146, 147, 150  
pigment gallstones, 52, 145, 147  
GB virus C (GBV-C), 75  
gene therapy, 50, 51, 58, 59, 103, 105, 111, 112, 115, 123, 124  
genetic mutations/genetic liver disease, 10, 32, 53-55, 57, 101, 103, 109-116  
genome, genomics, 3, 4, 10, 23, 28, 33, 35, 41, 43, 54, 61, 62, 65, 82, 90, 92, 93, 103, 108, 116, 138, 146, 153, 154  
Gilbert syndrome, 54, 56  
glutathione (GSH), 86, 88  
Golgi apparatus, 32, 33  
graft-versus-host disease, 53  
growth factors, 44, 45, 46, 47, 49, 75, 80, 112, 141

**H**

hemochromatosis (hereditary), 2, 6, 9, 108-116, 137, 138  
hepcidin, 111, 112, 116  
HFE gene, 111-113, 115, 116  
hemophilia, 50, 71, 75  
hepatic encephalopathy, 6, 11, 19, 20, 129, 131-134  
hepatic venous pressure gradient (HVPG), 129, 132  
hepatitis  
autoimmune, 5, 11, 14, 16, 17, 94-99, 101, 119, 165  
drug-induced, 82, 87  
viral, 1, 5, 9, 11-13, 19, 23, 24, 40, 42, 49, 60-69, 71, 72, 76, 82, 89, 95, 101, 104, 130, 138, 168  
hepatitis A, 2, 9, 12, 13, 21, 60-64, 67, 68, 74, 77, 102  
hepatitis B, 6, 12, 13, 16, 17, 19, 21, 24, 39, 60-77, 101, 102, 105, 119, 137-141, 166  
hepatitis B surface antigen (HBsAg), 61-66, 73  
HBV DNA integration and hepatocellular carcinoma, 17, 63, 137, 138  
HBV vaccination, 2, 9, 12, 21, 61-63, 65-69, 74, 102, 139, 166  
hepatitis C, 2, 6, 9, 11-13, 14, 16, 17, 19-21, 24, 60-69, 71-73, 75-77, 112, 113, 116, 119, 121-124, 126, 137, 138, 141, 165, 166, 168  
Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C), 68  
hepatitis C immune globulins (HCIG), 65, 69, 123  
Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C (PedSC), 68  
recurrence, 67, 122-124, 126  
hepatitis D, 13, 60-62, 64, 67-69  
hepatitis E, 60-62, 64, 68, 69  
woodchuck hepatitis virus, 138, 139  
hepatoblast, 44, 45  
hepatoblastoma, 17, 137  
hepatocarcinogenesis, 5, 6, 45, 46, 48, 51, 104, 136, 138, 139, 141-143  
hepatocellular carcinoma (HCC), 1, 6, 11, 15-17, 24, 63, 81, 92, 110, 119, 121, 124, 135-143, 152, 155, 167  
fibrolamellar, 137  
Milan criteria, 139, 141  
hepatocyte, 30-36, 39, 40, 44-51, 53-59, 61, 65, 73, 79, 80, 103, 105, 111, 124, 136, 138, 139  
hepatoprotective therapy, 42, 58, 91, 93  
hepatopulmonary syndrome, 6, 110, 129, 131-134  
hepatorenal syndrome, 6, 129, 131-134  
hepatotoxicity, 5, 86-93

herbal medications, 5, 54, 75, 81, 87, 89, 90, 142

silymarin, 81, 82, 85

Yin Zhi Huang, 54

hereditary tyrosinemia, 102, 109

highly active antiretroviral therapy (HAART)—See antiviral therapy, for HIV infection

HLA haplotype, 87, 89, 96, 99, 111

Human Genome Project, 3, 4, 10, 28, 33, 54

human immunodeficiency virus-1 (HIV), 2, 5, 19, 24, 67, 70-77, 89, 166

coinfection (with hepatitis virus and HIV), 24, 67, 70-72, 74, 76

Human Proteome Project, 4, 28, 33

hyperbilirubinemia, 54, 56, 58, 59

## I

idiopathic vanishing bile duct syndrome, 53, 87

imaging, 35, 49, 51, 75, 80, 83, 95, 99, 113, 116, 133, 139, 141-143, 146, 148-150, 152-159, 166

criteria, 155, 156, 158, 159, 168

functional, 141, 143, 154

image-guided therapy, 153, 154, 157

molecular, 148-150, 154, 156, 157, 159

optical, 156, 159

paramagnetic polymerized nanoparticles, 154

immune system, 40, 66, 73, 82, 89, 90, 93, 98, 99, 123

adaptive, 40, 57, 58, 66, 90

cells of, 32, 41, 46, 49, 66, 70, 79, 82, 94, 96, 97, 99, 111

innate, 40, 66, 89, 90, 93, 98, 99, 123

immunosuppression/immunosuppressants, 91, 95, 96, 98, 101, 102, 104, 120-123, 126

inflammation, 5, 14, 35, 39-43, 48, 49, 51, 53, 78, 79, 81, 82, 89, 91, 95, 97, 99, 101, 136, 147-150, 156, 159

injury, 1, 2, 5, 11, 14, 19, 20, 23, 32, 37-46, 48, 49, 51, 53-55, 58, 65, 71-76, 78-82, 84-93, 95-99, 101, 103, 109, 112, 113, 115, 116, 122, 124, 130, 136, 156, 165, 166

drug/toxin-induced—See drug-induced liver disease

hypoxic injury, 41, 43

ischemia-reperfusion injury, 41, 43, 124

insulin-sensitizing agents, 75, 80, 85, 141

interdisciplinary, 36, 48, 50, 97, 99, 103, 149

interferon/peginterferon alfa—See antiviral therapy

iron overload—See hemochromatosis

## J

Jagged-1, 57, 102

jaundice, 11, 13, 14, 20, 53, 54, 56, 64, 92, 129, 130, 153

## K

kernicterus, 56

kidney disease, 6, 11, 19, 64, 67, 69, 110, 112, 116, 129-134, 166

Kupffer cell, 32, 35, 36, 41, 48, 49, 73, 80, 89

## L

lactic acidosis, 72, 75

L-carnitine—See nutritional supplements

life cycle (viral), 62-66, 68, 69

lipid, 5, 31, 33, 34, 36, 53-56, 58, 59, 79-81, 83, 85, 102, 146, 147

lipoprotein, 33, 34

lysosome, 32

## M

magnetic resonance cholangiopancreatography (MRCP), 153

magnetic resonance imaging (MRI), 83, 139, 153-158

major histocompatibility complex (MHC), 123

metabolic disorders, 1, 11, 17, 40, 50, 51, 101-103, 106, 110, 119, 124-126

metabolome, metabolomics, 74, 76, 81, 83, 85, 90-93, 103, 147, 149, 150, 166

microarray

gene, 33

RNA, 154

microtubules, 34

mitochondria, 32, 33, 35, 71, 72, 75-77, 89, 90, 95, 96, 101, 104

mitochondrial injury, 71, 72, 75, 76, 90

mitochondrial hepatopathies, 101, 105

Model for End-stage Liver Disease (MELD), 120, 124-126

motors, 33, 34, 55

Mycobacterium avium complex (MAC), 71

myofibroblast, 32, 39

## N

N-acetylcysteine (NAC), 85, 87, 91, 133, 134  
National Cancer Institute (NCI), 22, 23, 43, 163  
National Center for Complementary and Alternative Medicine (NCCAM), 22, 23, 163  
National Center for Research Resources (NCRR), 22, 23, 163  
National Center on Minority Health and Health Disparities (NCMHD), 22, 23, 163  
National Health and Nutrition Examination Survey (NHANES), 105  
National Heart, Lung, and Blood Institute (NHLBI), 22, 23, 163  
National Human Genome Research Institute (NHGRI), 22, 23, 163  
National Institute on Aging (NIA), 22, 23  
National Institute on Alcohol Abuse and Alcoholism (NIAAA), 22, 23, 163  
National Institute of Allergy and Infectious Diseases (NIAID), 22, 23, 163  
National Institute of Child Health and Human Development (NICHD), 22, 23, 85, 163  
National Institute of Dental and Craniofacial Research (NIDCR), 22, 23  
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 3, 4, 22, 23, 25, 26, 51, 85, 161, 162  
Division of Digestive Diseases and Nutrition (DDDN), 3, 4, 25, 161  
Liver Disease Research Branch (LDRB), 3, 4, 25, 26, 161, 162  
National Institute on Drug Abuse (NIDA), 22, 23, 163  
National Institute of Environmental Health Sciences (NIEHS), 22, 23, 163  
National Institute of Mental Health (NIMH), 22, 23  
National Institute of Nursing Research (NINR), 22, 23, 163  
necrosis, 40, 46, 79, 86, 90  
neonatal cholestatic syndromes, 57, 58, 103, 104, 106, 109, 119  
neurological disease, 54, 56, 75, 110, 114, 121, 129, 166  
nitrosative stress, 41, 43  
nonalcoholic fatty liver disease—See fatty liver disease  
nonalcoholic steatohepatitis (NASH)—See fatty liver disease  
noninvasive tools—See biomarkers and imaging  
nonmammalian model organisms  
  *Xenopus*, 47  
  *Zebrafish*, 47  
Notch, 57, 102  
nuclear receptors, 54, 55, 88  
orphan, 54, 88

## nucleus, 32

nucleoside analogues, 63, 65, 75, 90, 141  
nutritional supplements  
  L-carnitine, 87  
  S-adenosylmethionine, 24, 80, 81, 85, 91  
  vitamin E, 81, 83, 85

## O

obesity, 14, 55, 79, 80, 82, 84, 89, 104, 138, 145, 149  
Office of the Director (OD), 22, 23  
  Office of AIDS Research, 163  
  Office of Dietary Supplements, 163  
  Office of Rare Diseases, 163  
  Office of Research on Women's Health, 163  
organelle, 32, 33, 35, 43, 55, 89, 90  
organogenesis—See development  
oval cell, 45-47  
overweight, 2, 14, 78, 82, 104  
oxidative stress, 41, 43, 80, 82, 89, 50

## P

partial hepatectomy, 44-48  
Pediatric model for End-stage Liver Disease (PELD), 120, 124-126  
peginterferon—See antiviral therapy  
peroxisome, 32, 33  
phase 1-3 enzymes (drug metabolism), 88  
phospholipids, 33, 52, 53, 55, 146  
plasma membrane, 32-34, 36, 55  
polarity, 30, 33-36  
polycystic liver disease, 55, 108-110, 112, 116, 145  
porphyria, 6, 50, 108-112, 114-116  
  acute intermittent porphyria (AIP), 108, 110, 111  
  erythropoietic protoporphyrin (EPP), 108, 110, 112  
  hereditary coproporphyrin (HCP), 108, 110  
  porphyria cutanea tarda (PCT), 108, 110, 112  
  variegate porphyria (VP), 108, 110  
porphyrin, 55, 109, 110, 112, 115  
portal hypertension, 1, 6, 11, 20, 39, 110, 127-134, 153, 155, 156  
portal vein, 10, 11, 30, 31, 52, 128, 139  
positron emission tomography (PET), 154-156, 159  
post-transplant lymphoproliferative disease (PTLD), 123, 126

pregnancy (liver diseases in), 53, 55, 57, 59  
primary biliary cirrhosis (PBC), 2, 5, 11, 14, 16, 20, 40, 53, 94-99, 119  
    antimitochondrial antibodies (AMAs), 95, 96  
    antinuclear antibodies (ANAs), 95  
primary sclerosing cholangitis (PSC), 5, 11, 14, 16, 54, 94-99, 145, 148, 153  
    link to inflammatory bowel disease, 95-97, 99  
primordium, 44-47, 51  
progenitor cell, 40, 45-49  
programmed cell death—See apoptosis  
progressive familial intrahepatic cholestasis (PFIC), 53, 55, 59, 101-103, 105  
proliferation (cell), 32, 44, 47, 49, 51, 96, 139  
proteasome, 32, 35  
proteome, proteomics, 4, 28, 33, 35, 36, 41-43, 48, 51, 74, 76, 81, 83, 85, 90-93, 98, 103, 122, 133, 140, 146, 147, 149, 150, 154, 166  
prothrombin time, 120  
pruritus, 57-59, 129

## Q

quality of life, 2, 12, 20, 104, 120, 123, 126, 129, 130, 132, 134, 140-142, 165, 167

## R

reactive nitrogen species—See nitrosative stress  
reactive oxygen species (ROS)—See oxidative stress  
redox state—See oxidative stress  
regeneration, 5, 11, 21, 39, 41-51, 91, 112, 118, 122, 126, 132, 134, 156  
repair, 5, 39-43, 112  
replication  
    cell, 44, 45, 47  
    viral, 62-69, 124  
replicon, 63  
ribavirin—See antiviral therapy

## S

S-adenosylmethionine (SAM-e)—See nutritional supplements  
scarring—See fibrosis  
sepsis, 53, 56, 57, 59  
septum transversum mesenchyme, 44, 46  
shock, 57  
silymarin—See herbal medications  
sinusoid, 10, 30-32, 39, 40, 43, 56  
siRNA, 50, 103, 106  
small molecule therapy, 41, 43, 49, 51, 57, 58, 64, 66-69, 103, 105, 106, 131, 134  
special populations, 15, 67, 85, 166  
    ethnicity/race, 14, 15, 19, 66, 71, 113, 115, 116, 145, 148, 150  
    gender, 2, 14, 15, 19, 95, 104, 137, 145  
    pediatric, 16, 17, 23, 58, 68, 100-106  
sphincter of Oddi, 147, 149, 150  
stellate cell, 32, 34-36, 39, 47-49, 73, 89  
stem cell, 46, 48-51, 103, 105, 106, 115, 116, 124  
surveillance (epidemiologic), 13, 14, 19, 20, 28, 61, 73, 92, 105, 111, 138, 140, 143

## T

tissue bank, 6, 142, 143, 155, 159, 161  
tissue culture—See cell culture  
total parenteral nutrition (TPN)-associated liver disease, 17, 53, 57, 59, 79, 101  
training, 2, 23, 36, 93, 149, 158  
transcription factors, 45-47, 79, 88  
transcriptome, transcriptomics, 90-93  
transgenic—See animal models  
transjugular intrahepatic portosystemic shunts (TIPS), 131, 153, 155  
translation, 3, 4, 21, 28, 33, 36, 39, 40, 42, 43, 51, 57, 65, 72, 92, 99, 110, 147  
transplantation, 117-126  
    Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL), 51, 68, 125

- extended criteria donors, 124  
graft tolerance/rejection, 50, 51, 53, 104, 120-126  
Immune Tolerance Network (ITN), 125  
living donor liver transplantation, 5, 6, 16, 21, 45, 49-51, 102, 118-126, 141, 155, 166  
organ donation/waiting list, 102, 119, 120, 124, 125, 129  
reduced size liver transplantation, 20, 102, 118  
Scientific Registry of Transplant Recipients (SRTR), 15, 16, 125  
split liver transplantation, 45, 102, 119  
Studies of Pediatric Liver Transplantation (SPLIT), 105, 125  
transporters (plasma membrane), 32-34, 36, 54-57, 59, 88, 111, 112  
triglyceride, 33, 79, 81, 84
- X**
- xenobiotic, 32, 54, 57, 87
- Y**
- Yin Zhi Huang—See herbal medications
- Z**
- zonality, 31, 35

**U**

- UDP-glucuronosyl transferase, 54, 58  
ultrasound (US), 83, 142, 153-155  
urea cycle disorders, 50  
ursodiol, 95-99  
    High-Dose Ursodiol Trial, 149

**V**

- vaccine, 2, 9, 12, 21, 61-69, 71, 74, 102, 139, 166  
vanishing bile duct syndrome—See idiopathic vanishing bile duct syndrome  
veno-occlusive disease, 40  
vesicle trafficking, 32, 34, 36

**W**

- wedged hepatic venous pressure (WHVP), 132  
Wilson ATPase, 111, 114, 116  
Wilson disease, 2, 6, 9, 101, 102, 108-116